STRM.BIO

STRM.BIO is developing simpler, safer and more practical gene therapies through the use of microvesicles (MVs). MVs are a new player to the gene therapy delivery technology landscape. MVs are naturally secreted from multiple types of cells and can deliver DNA and other molecules between cells. STRM.BIO is designing their platform to generate off-the-shelf banked gene therapy products that completely bypass the liver and is compatible with diverse cargos and clinical indications. STRM.BIO have shown their MVs can be repeatedly dosed in non-human primates with no apparent toxicity or inflammation.

Jobs: